Literature DB >> 33483537

Suppression of IL-23-mediated psoriasis-like inflammation by regulatory B cells.

Kie Mizumaki1, Motoki Horii1, Miyu Kano1, Akito Komuro1,2, Takashi Matsushita3.   

Abstract

Psoriasis is an inflammatory cutaneous disease mediated by T-cell dependent immune responses; however, B cells are also considered to play an important role its development. Regulatory B cells (Bregs) regulate immune responses negatively through interleukin-10 (IL-10) production. This study aimed to investigate the role of Bregs in IL-23-mediated psoriasis-like inflammation in mice. Psoriasis-like inflammation was induced in B cell-specific phosphatase and tensin homolog (PTEN)-deficient mice, in which Bregs were significantly expanded, and in their controls, by intradermal injection of 20 μL phosphate-buffered saline (PBS) containing 0.5 μg rmIL-23 into one ear, every other day for 16 days. IL-23-mediated psoriasis-like inflammation was suppressed in B cell-specific PTEN-deficient mice along with decreased ear thickness and epidermal thickness on day 15. Moreover, adoptive transfer of B1 B cells suppressed IL-23-mediated psoriasis-like inflammation. rmIL-23-injected B cell-specific PTEN-deficient mice showed expanded regulatory T cells (Tregs) in the spleen and draining lymph nodes along with increased Bregs. Further, T helper (Th) 17 differentiation in the rmIL-23-injected ear was suppressed in B cell-specific PTEN-deficient mice. Overall, these results indicate that increased Bregs suppress IL-23-mediated psoriasis-like inflammation through Treg expansion and inhibition of Th17 differentiation. Thus, targeting Bregs may be a feasible treatment strategy for psoriasis.

Entities:  

Year:  2021        PMID: 33483537     DOI: 10.1038/s41598-021-81588-8

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  39 in total

Review 1.  Regulation of immunity and autoimmunity by B cells.

Authors:  Claudia Mauri
Journal:  Curr Opin Immunol       Date:  2010-11-17       Impact factor: 7.486

2.  Development of psoriasis after B cell depletion with rituximab.

Authors:  Shouvik Dass; Edward M Vital; Paul Emery
Journal:  Arthritis Rheum       Date:  2007-08

Review 3.  B lymphocytes: how they develop and function.

Authors:  Tucker W LeBien; Thomas F Tedder
Journal:  Blood       Date:  2008-09-01       Impact factor: 22.113

Review 4.  Psoriasis.

Authors:  Frank O Nestle; Daniel H Kaplan; Jonathan Barker
Journal:  N Engl J Med       Date:  2009-07-30       Impact factor: 91.245

5.  Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma.

Authors:  F Mielke; J Schneider-Obermeyer; T Dörner
Journal:  Ann Rheum Dis       Date:  2008-07       Impact factor: 19.103

Review 6.  Novel regulatory functions for Toll-like receptor-activated B cells during intracellular bacterial infection.

Authors:  Simon Fillatreau
Journal:  Immunol Rev       Date:  2011-03       Impact factor: 12.988

7.  Cyclosporin A for psoriasis.

Authors:  W Mueller; B Herrmann
Journal:  N Engl J Med       Date:  1979-09-06       Impact factor: 91.245

Review 8.  B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer.

Authors:  David J DiLillo; Takashi Matsushita; Thomas F Tedder
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

9.  Determinants of quality of life in patients with psoriasis: a study from the US population.

Authors:  Joel M Gelfand; Steven R Feldman; Robert S Stern; John Thomas; Tara Rolstad; David J Margolis
Journal:  J Am Acad Dermatol       Date:  2004-11       Impact factor: 11.527

Review 10.  The IL-23/Th17 axis in the immunopathogenesis of psoriasis.

Authors:  Antonella Di Cesare; Paola Di Meglio; Frank O Nestle
Journal:  J Invest Dermatol       Date:  2009-03-26       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.